64. inCB (2016) Availability of internationally controlled drugs: ensuring adequate access for medical and scientific purposes : indispensable, adequately available and not unduly restricted, Supplement to the INCB report for 2015 [pdf]. Viena: Conselho Internacional para o Controlo de Estupefacientes. disponível em: https://www.unodc.org/documents/drug-prevention-and-treatment/inCB_access_supplement-ar15_availability_english.pdf (acesso de 22 de janeiro de 2019).

65. nações unidas, assembleia Geral (2016) Our joint commitment to effectively addressing and countering the world drug problem, Trigésima sessão especial da assembleia Geral. nova iorque: nações unidas. un doc a/res/s-30/1. inCB (2016) availability of internationally controlled drugs: ensuring adequate access for medical and scientific purposes : indispensable, adequately available and not unduly restricted, supplement to the inCB report for 2015 [pdf]. Viena: Conselho internacional para o Controlo de estupefacientes. disponível em: https://www.unodc.org/documents/drug-prevention-and-treatment/inCB_access_supplement-ar15_availability_english.pdf (acesso de 22 de janeiro de 2019).

66. inCB (2019) Progress in ensuring adequate access to internationally controlled substances for medical and scientific purposes, Supplement to the INCB report for 2018 [pdf]. Viena: Conselho internacional para o Controlo de estupefacientes. un doc. e/inCB/2018/1/supp.1, preface. disponível em: https://www.incb.org/documents/publications/annualreports/ar2018/supplement/supplement_e_ebook.pdf (acesso de 6 de março de 2019)

67. Consultar: Hallam, C., Bewley-Taylor, d., Jelsma, M. (2014) Scheduling in the international drug control system. amsterdam: Transnational institute, series on legislative reform of drug policies no. 25, Tni/idpC. disponível em: https://www.tni.org/files/download/dlr25_0.pdf (acesso de 22 de janeiro de 2019)

68. oMs (2012) WHO Expert Committee on Drug Dependence, Thirty-fifth report, WHo Technical report series 973, Genebra: organização Mundial da saúde, p 9. disponível em: https://apps.who.int/iris/bitstream/handle/10665/77747/WHo_trs_973_eng.pdf (acesso de 22 de janeiro de 2019)

69. inCB (2011) Report of the International Narcotics Control Board for 2010. Viena: Conselho internacional para o Controlo de estupefacientes, parág. 284-287. disponível em: http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&an=387587 (acesso de 20 de janeiro de 2019)

70. Hallam, C., Bewley-Taylor, d., Jelsma, M. (2014) Scheduling in the international drug control system [pdf]. amesterdão: Transnational institute, series on legislative reform of drug policies no. 25, Tni/idpC, pp. 13-14. disponível em: https://www.tni.org/files/download/dlr25_0.pdf (acesso de 22 de janeiro de 2019)

71. para o caso de ayahuasca, consultar: sánchez, C. & Bouso, C. (2015) Ayahuasca: From the Amazon to the Global Village - An analysis of the challenges associated with the globalisation of ayahuasca, Tni policy briefing 43. disponível em: https://www.tni.org/files/publication-downloads/dpb_43_eng_web_19122015.pdf (acesso de 22 de janeiro de 2019)

72. Metaal, p. & Henman, a. (2014) Time for a Wake-up Call: An historical and ethnographic approach to the Regulation of Plant-based Stimulants, TNI Policy briefing [pdf]. amsterdão: Transnational institute. disponível em: https://www.tni.org/files/download/dlr_27_eng-web.pdf (acesso de 22 de janeiro de 2019).

73. Carrier, n., & Gezon, l. (2009) Khat in the Western Indian Ocean: Regional Linkages and Disjunctures. Études océan indien, 42-43(plantes et sociétés), 271-297. [11]. https://doi.org/10.4000/oceanindien.851

74. oMs (2006) Assessment of khat (Catha edulis forsk), WHo expert Committee on drug dependence, 34th eCdd 2006/4.4 [pdf]. Genebra: organização Mundial da saúde. disponível em: http://www.who.int/medicines/areas/quality_safety/4.4KhatCritreview.pdf (acesso de 23 de janeiro 2019).

75. inCB (2007) Report of the International Narcotics Control Board for 2006 [pdf]. Viena: Conselho internacional para o Controlo de estupefacientes, parág. 556. disponível em: https://www.incb.org/documents/publications/annualreports/ar2006/ar_06_english.pdf (acesso de 23 de janeiro 2019)

76. nabben, T. and Korf, d. J. (2017) Consequences of criminalisation: the Dutch khat market before and after the ban. Drugs: Education, Prevention and Policy, 24(4), pp. 332–339. doi: 10.1080/09687637.2017.1338669.

77. Central statistical agency (2018) agricultural sample survey 2017/18 (2010 e.C.), Volume i, report on area and production of Major Crops (private peasant Holdings, Meher season), statistical Bulletin 586. addis ababa: The federal democratic republic of ethiopia, p. 14.

78. unodC (2018) World Drug Report 2018, Executive Summary [pdf]. Vienna: united nations office on drugs and Crime, p. 9. disponível em: https://www.unodc.org/wdr2018/prelaunch/Wdr18_Booklet_1_exsuM.pdf (acesso de 24 de janeiro 2019).

79. Cochrane, l., & o’regan, d. (2016) Legal Harvest and Illegal Trade: Trends, Challenges and Options in Khat Production in Ethiopia. international Journal of drug policy, p. 28. http://dx.doi.org/10.1016/j.drugpo.2016.02.009

80. ibid., p. 33.81. Tanguay, p. (2011) Kratom in Thailand. ssrn scholarly paper id 1908849. London: International Drug Policy Consortium. disponível

em: https://papers.ssrn.com/abstract=1908849 (acesso de 24 de janeiro de 2019).82. Henningfield, J. e., fant, r. V. and Wang, d. W. (2018) The abuse potential of kratom according the 8 factors of the controlled

substances act: implications for regulation and research. psychopharmacology, 235(2), pp. 574. doi: 10.1007/s00213-017-4813-4.83. usdea (2016) Schedules of Controlled Substances: Temporary Placement of Mitragynine and 7-Hydroxymitragynine Into Schedule

I. Federal Register. disponível em: https://www.federalregister.gov/documents/2016/08/31/2016-20803/schedules-of-controlled-substances-temporary-placement-of-mitragynine-and-7-hydroxymitragynine-into (acesso de 24 de janeiro 2019).

84. Gianutsos, G. (2017) The DEA Changes Its Mind on Kratom. us pharm. 2017;41(3):7-985. Henningfield (2018) op. cit., p. 575.86. ibid. p. 585.87. Georgia House of representatives (2019) House Bill 551: Controlled substances; kratom; provisions [pdf]. atlanta: Georgia

General assembly. disponível em: http://www.legis.ga.gov/legislation/20192020/183343.pdf (acesso de 22 de abril de 2019) utah senate (2019) Kratom Consumer protection act [pdf]. salt lake City: state of utah. disponível em: https://www.billtrack50.com/Billdetail/1005796 (acesso de 22 de abril de 2019).

88. sattaburuth, a. (2018) Medical cannabis, kratom bill passed by NLA. Bangkok: Bangkok post. disponível em: https://www.bangkokpost.com/news/general/1600566/medical-cannabis-kratom-bill-passed-by-nla (acesso de 11 de fevereiro 2019).

89. Consultar: aguilar, s., et al. (2018) Medicinal cannabis policies and practices around the world [pdf]. london: international drug policy Consortium. disponível em: https://idpc.net/publications/2018/04/medicinal-cannabis-policies-and-practices-around-the-world (acesso de 11 de fevereiro 2019).

II SÉRIE-A — NÚMERO 127______________________________________________________________________________________________________________________

354